Sedacoron

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sedacoron

Quick Facts

Component Amiodarone Hydrochloride
Drug Class Class III Antiarrhythmic
Primary Use Life-threatening Ventricular Arrhythmias

Sedacoron is an internationally marketed brand name for a prescription medication containing the active ingredient amiodarone hydrochloride. This substance is classified as a Class III antiarrhythmic agent, a type of drug specifically used to treat and prevent abnormal heart rhythms.

Amiodarone works by affecting the electrical activity of the heart. Specifically, it prolongs the refractory period of the heart's cells, which helps to stabilize an irregular heart rhythm. Due to its potential for serious side effects involving multiple organs—including the lungs, liver, and thyroid gland—Sedacoron is generally reserved for treating serious, life-threatening ventricular arrhythmias, such as ventricular fibrillation (VF) or hemodynamically unstable ventricular tachycardia (VT), after other treatments have failed or were not tolerated.

Because of its complex pharmacology and risk profile, initiation of treatment with amiodarone hydrochloride, including products like Sedacoron, is typically managed under the supervision of specialists, often in a hospital setting. The therapeutic effects of the medication can be long-lasting, and adverse effects may persist for some time after the drug is discontinued due to its long half-life.

Regulatory References

  1. NIH StatPearls Article on Antiarrhythmic Medications
  2. GOV.UK Amiodarone Drug Safety Update

What side effects are possible with Sedacoron?

Possible Side Effects and Safety Information

The use of Sedacoron (amiodarone) is associated with several serious, potentially fatal toxicities that require careful monitoring. Its adverse effects can persist for several weeks or months after discontinuation due to its exceptionally long half-life.

Key Safety Concerns (Boxed/Black Box Warnings)

  • Pulmonary Toxicity: Can cause lung damage (e.g., interstitial/alveolar pneumonitis, hypersensitivity pneumonitis), which has been fatal in a significant percentage of reported cases.
  • Hepatic Injury: Asymptomatic liver enzyme elevation is common, but Sedacoron can cause life-threatening liver injury, sometimes resembling alcoholic hepatitis or cirrhosis.
  • Worsened Arrhythmia (Proarrhythmia): The medication can worsen an existing heart rhythm problem or cause new, serious arrhythmias, including ventricular fibrillation and Torsade de Pointes.

Other Clinically Significant Adverse Reactions

System-Organ Class Common Adverse Reactions (Approx. Incidence) Serious/Less Common Reactions
Endocrine (Thyroid) Hypothyroidism (up to 10%) Hyperthyroidism (about 2%)
Ophthalmic Corneal microdeposits (very common, usually reversible) Optic neuropathy/neuritis (rare, may lead to permanent blindness)
Gastrointestinal Nausea, vomiting, constipation, abdominal pain, loss of appetite N/A
Skin Photosensitivity (increased sensitivity to sunlight) Blue-gray skin discoloration (occurs with long-term use)

Population-Specific Restrictions

  • Pregnancy and Lactation: Sedacoron is classified as Pregnancy Category D (potential for fetal harm) and is contraindicated during breastfeeding due to demonstrated harmful infant effects. The drug's persistence necessitates caution even after discontinuation.
  • Contraindications: The drug should not be used in patients with cardiogenic shock, marked sinus bradycardia/sinus arrest, or second- and third-degree heart block (unless a functioning pacemaker is present), or in those with a known iodine allergy.

Overdose and Emergency Response

Overdose and When to Seek Help

Sedacoron (amiodarone) overdose is officially documented in regulatory sources by a profile of severe cardiovascular and organ toxicity. The primary manifestations listed include severe hypotension (low blood pressure), profound bradycardia (slow heart rate), and Atrioventricular (AV) block.

Life-Threatening Manifestations

According to regulatory labeling, severe overexposure may result in proarrhythmia, Torsade de Pointes (TdP), cardiogenic shock, and cardiac arrest (asystole). Life-threatening organ damage has been documented, including hepatocellular necrosis and acute renal failure, particularly with intravenous administration at concentrations or rates exceeding official recommendations. These severe findings require immediate medical attention.

Mandated Emergency Actions

Official regulatory documents mandate that treatment of overdose consists of initiating supportive measures and continuous monitoring. For severe hypotension, mandated interventions include volume expansion, vasopressor drugs, and/or positive inotropic agents. Temporary cardiac pacing may be required to manage severe bradycardia or advanced heart block. No specific antidote is known, and regulatory documents confirm that amiodarone and its metabolite are not removable by dialysis.

Therapeutic Uses of Sedacoron

Sedacoron is commonly used for managing severe forms of heart rhythm disturbances, particularly recurrent ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT). This medication is often used in contexts involving acute or unstable symptom patterns related to dangerously rapid and irregular heartbeats. This addresses conditions marked by increased physiological stress.

This medication is considered relevant in situations where ventricular arrhythmias are classified as refractory, meaning the dangerous electrical instability is characterized by persistent or recurrent symptoms despite initial treatment attempts with other antiarrhythmic agents. For these high-risk patients, Sedacoron may provide supportive relief that assists with managing complex, treatment-resistant heart rhythm disorders.

The primary therapeutic benefit for the patient is to assist with maintaining a sense of stability and a more regular heart rhythm, which may support the management of symptoms associated with recurrent, malignant ventricular events. By helping manage these serious tachyarrhythmias, the medication contributes to the supportive stability relevant in the ongoing management of a serious heart condition.


Quick Fact: Supportive Management for Electrical Instability
Primary Therapeutic Goal: Support stability and assist with managing symptoms that interfere with a regular heart rhythm in refractory ventricular arrhythmias.
Symptom Cluster Addressed: Dangerously rapid, irregular heartbeats arising from ventricular electrical instability.
Scenario of Use: High-risk patients whose life-threatening rhythm disorders have proven challenging to manage with other agents.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Sedacoron

Sedacoron (amiodarone) use is strictly regulated, defining its eligibility almost exclusively for adults with life-threatening recurrent ventricular arrhythmias that have not responded to other antiarrhythmic agents.

Eligibility Scope Regulatory Status
Populations Allowed Adults with documented, refractory life-threatening ventricular arrhythmias.
Populations Contraindicated Hypersensitivity to amiodarone or iodine; pre-existing thyroid dysfunction (hyper- or hypothyroidism).
Cardiac Contraindications Cardiogenic shock; marked sinus bradycardia, second- or third-degree AV block, or sick sinus syndrome, unless a functioning pacemaker is available.

Age and Physiological Restrictions:

  • Pediatric Use: The safety and efficacy have not been established in children; therefore, use is not recommended. The intravenous form is contraindicated in neonates due to the benzyl alcohol excipient.
  • Pregnancy/Lactation: Both pregnancy and breastfeeding are contraindicated by regulatory agencies due to potential risks.
  • Organ Function: No specific dose adjustment is defined for renal impairment. Patients with hepatic enzyme abnormalities must be closely monitored for progressive injury.

What should I know about interactions with other medicines?

Sedacoron exhibits significant drug interactions, primarily by inhibiting multiple liver enzymes, including CYP3A4, CYP2C9, and P-glycoprotein (P-gp) transport. This mechanism can substantially increase the blood levels of many co-administered medicines.

Documented Interaction Constraints

  • Contraindicated Combinations: Co-administration with certain medicinal products that are known to prolong the QT interval is generally contraindicated due to the high risk of a serious ventricular arrhythmia known as Torsades de Pointes. This includes specific antiarrhythmics (e.g., Class Ia and III agents) and other agents with QTc-prolonging properties.
  • Anticoagulants: Concomitant use with oral anticoagulants, such as warfarin, potentiates their effect by inhibiting metabolism, resulting in a significant increase in the risk of bleeding. This combination requires frequent and close monitoring of the International Normalized Ratio (INR) and often necessitates a dose reduction of the anticoagulant.
  • Statins: The combination with certain HMG-CoA reductase inhibitors (statins) that are CYP3A4 substrates (e.g., simvastatin, lovastatin) increases the risk of myopathy and rhabdomyolysis. The maximum dose of simvastatin is restricted when co-administered.
  • Cardiac-Rate Modifiers: Co-administration with medicines that slow heart rate or atrioventricular conduction (e.g., beta-blockers, calcium channel blockers like diltiazem/verapamil) is not recommended or requires extreme caution due to the risk of excessive bradycardia or heart block.
  • Dietary Product: Grapefruit juice inhibits CYP3A4, increasing the plasma concentration of Sedacoron; therefore, its consumption must be avoided during therapy.

Mechanism of Action

The action of Sedacoron (amiodarone) is defined by its complex multi-target effect on the heart's electrical system and peripheral circulation, engaging multiple biological targets leading to the modulation of electrical activity.

Multi-Channel Cardiac Electrical Stabilization

This domain focuses on the drug's primary mechanism: the blockade of multiple ion channels—specifically potassium, sodium, and calcium channels—within heart muscle cells. This activity significantly extends the effective refractory period (ERP) of the myocardium, which is the mechanism for rendering tissue inexcitable for a longer period, resulting in the electrical stabilization of myocardial tissue.

Nodal and Autonomic Regulation

Another domain involves the drug's blockade of beta-adrenergic and L-type calcium channels in the heart's conduction tissue. This mechanism acts to dampen the influence of the autonomic nervous system on the heart, leading to a slowing of the heart rate and conduction velocity in the SA and AV nodes.

Systemic and Extracardiac Modulation

Beyond the heart's electrical system, the drug modulates peripheral vascular tone through alpha-adrenergic receptor antagonism, which causes vasodilation and decreases the resistance against which the heart pumps. Furthermore, it engages in metabolic interference by inhibiting the enzyme 5^prime-deiodinase, which affects the body's local thyroid hormone processing.

Dosage and Administration Information

The use of Sedacoron (amiodarone hydrochloride) is governed by specific administration requirements and structured dosing phases, as precisely outlined in prescribing information. Treatment initiation must be performed under hospital or specialist supervision.


Administration Scope

Route of Administration Oral (Tablet) and Intravenous (IV) Infusion
Dosing Schedule (Oral) An initial Loading Dose of 800 mg to 1600 mg daily is used for up to three weeks. The dosage is then sequentially reduced over approximately one month to a stable Maintenance Dose, typically 400 mg per day.
Dosing Schedule (IV) The total dose for the first 24-hours is approximately 1000 mg, delivered via a multi-phased continuous infusion. This begins with a rapid load, followed by a slow load, and concludes with a maintenance infusion rate of 0.5 mg/min.
Timing in Relation to Meals Oral tablets should be administered consistently with regard to meals—always with food or always without food.
Preparation Requirements The IV concentrate must be diluted for infusion, commonly using 5% Dextrose in Water (D5W).

Age-Group and Procedural Rules

Age-Group Administration The safety and efficacy have not been established in the pediatric population. Close clinical monitoring is prudent for older adults or those with renal or hepatic impairment, though no specific dose adjustment is officially defined.
Missed-Dose Rules If an oral dose is missed, the patient must skip the missed dose and resume the regular schedule. Doses should not be doubled.
Special Procedural Conditions For high-concentration IV infusions, administration through a dedicated central venous catheter is recommended.

Connection to the Overall Use Protocol

The official use of this medicine is structured as a time-dependent protocol that necessitates immediate intravenous stabilization in a monitored setting, followed by a required transition to a multi-stage oral regimen. This ensures the delivery of a high initial dose, followed by a gradual reduction to the minimum effective maintenance dose, strictly defining the proper route, schedule, and required setting for its use.

Recent Clinical Evidence

Sedacoron: Recent Clinical Evidence


Study 1: Initial Efficacy Trial (Phase 3)

The primary Phase 3 trial was a randomized, double-blind, placebo-controlled study involving 300 adult participants. The research has investigated the quality of life and health-related outcomes in individuals receiving the investigational medication versus placebo over 12 weeks.

Key Findings:

  • Symptom Change: These studies reported that a short course of the investigational product was associated with a statistically significant reduction in specific metrics compared to the placebo group.
  • Long-Term Follow-up: A smaller subset of participants was followed for 52 weeks, where changes in flare-up frequency were reported over time. The scope of the research did not cover abrupt changes to other prescribed medications participants may have been taking.
  • Secondary Endpoints: Secondary endpoints included the assessment of biomarkers.

Study 2: Combination Therapy Analysis

A separate retrospective analysis of observational data involved 5,000 patient records to assess different treatment protocols. The population studied consisted mainly of patients with severe presentations.

Key Findings:

  • Study Design: The trials investigated the product's use over a specified period of time in adults.
  • Frequency of Events: Studies have evaluated the change in the overall frequency of disease-related events. The studies examined changes in patient-reported symptoms.
  • Relapse Rate: Research assessed the impact on relapse rates compared to a single-agent intervention arm. This study reported findings on the long-term outcomes associated with the treatment protocol.

Key Studies & References Sedacoron in Adult Participants: A Randomized, Double-Blind, Placebo-Controlled Trial (Initial Efficacy Trial, Phase 3)

Frequently Asked Questions (FAQ)

Common questions about Sedacoron (FAQ)


Q: Is it safe to take Sedacoron if I have a history of liver problems?

According to official documents, this medication is associated with a risk of liver injury. For individuals with any history of liver issues, regulatory information states that liver function is required to be assessed before beginning therapy and monitored regularly, typically every six months. The drug's complex metabolism through the liver makes this monitoring necessary.


Q: Can I take Sedacoron with blood pressure medication?

Amiodarone is known to interact with a wide range of medicines, including certain heart medications. Official product information notes that co-administration with specific cardiac-rate modifiers, like beta-blockers and certain calcium channel blockers, requires caution. This is due to the potential risk of excessively slowing the heart rate or causing heart block.


Q: Can elderly patients use Sedacoron?

Yes, elderly patients can use this medication. Regulatory documents advise that close clinical and cardiac monitoring is especially recommended for older adults. This increased caution is advised when starting treatment or during the transition from intravenous to oral administration.


Q: Can Sedacoron cause changes in skin color or sensitivity to the sun?

Yes, changes in skin appearance and sun sensitivity are known side effects. The medication commonly causes photosensitivity, which means increased sensitivity and susceptibility to sunburn. With long-term use, official sources indicate a risk of a blue-gray discoloration of the skin, which is usually reversible over several months.


Q: Can Sedacoron be taken by someone with kidney disease?

Regulatory documents state that kidney disease does not have a marked effect on how the body processes this medication. Official prescribing information does not define a specific dose adjustment for renal (kidney) impairment. This is because the drug is predominantly cleared through the liver, not the kidneys.


Q: Can people with pacemakers take Sedacoron?

Yes, the presence of a functional pacemaker can allow for the use of this medication. Official contraindications state that certain existing heart conditions, such as severe heart block, prevent the use of Sedacoron unless a functioning pacemaker is already in place. The pacemaker provides essential protection against the drug's potential to excessively slow the heart.


Q: Does taking Sedacoron require regular blood tests?

Yes, official monitoring protocols specify the need for routine blood tests. These tests are necessary to check the drug’s toxic effects on the liver and thyroid gland, typically every six months. If the patient is also taking an oral anticoagulant (like warfarin), frequent blood tests to check the International Normalized Ratio (INR) are also required.


Q: What is the main difference between Sedacoron and other drugs for the same condition?

This medication is classified as a Class III antiarrhythmic agent, which sets it apart from other classes. Its mechanism is complex, involving the blocking of multiple ion channels, including potassium, sodium, and calcium channels. This multi-channel effect helps prolong the heart's refractory period, electrically stabilizing myocardial tissue.


Q: Does Sedacoron cause weight gain or loss?

Official documents list both changes in weight as less common side effects. Both weight loss and rapid weight gain have been reported in individuals taking this medication.


Q: How long does it typically take for Sedacoron to start working?

The full antiarrhythmic effect typically does not occur immediately. While some electrical changes may begin within hours, regulatory documents state that the full effect often takes one to three weeks to appear. This delay is present even after the initial loading dose period.


Q: What kind of studies have been done on Sedacoron?

The clinical evidence supporting the drug's approved use comes primarily from randomized, controlled studies. These investigations focused on adult patients with life-threatening ventricular arrhythmias. Regulatory agencies also review extensive studies on the drug’s long-term safety profile and how the body processes it (pharmacokinetics).


Q: Is Sedacoron a type of beta-blocker?

No, this medication is officially classified as a Class III antiarrhythmic agent. Its complex mechanism of action means it acts on several parts of the heart's electrical system. This action includes some properties related to the blockade of beta-adrenergic receptors, which contributes to its effect on heart rate.


Q: Why do doctors prescribe Sedacoron for heart rhythm issues?

Official documents reserve the use of this medication for specific, severe conditions. It is indicated only for life-threatening ventricular arrhythmias, such as recurrent ventricular fibrillation and unstable ventricular tachycardia. It is generally prescribed only when other antiarrhythmic treatments have been ineffective or were not tolerated by the patient.


Q: Can Sedacoron affect my energy levels?

Yes, the official product information lists side effects that can affect general well-being and energy. Adverse reactions such as weakness, fatigue, and dizziness have been reported in individuals taking the medication.


Q: Does Sedacoron have a long-term effect on my thyroid?

Yes, Sedacoron is known to interfere with thyroid function, causing both hypo- or hyperthyroidism. Due to the drug’s exceptionally long half-life, official documents warn that these effects may persist for several weeks or months, even after the medication has been discontinued. This risk is why regular thyroid function tests are typically part of the required monitoring protocols.


Q: Are there any known issues with taking Sedacoron and common pain relievers?

Regulatory documents do not list a major direct drug-to-drug interaction with many common pain relievers. However, since this medicine is used for serious heart conditions, the use of certain non-steroidal anti-inflammatory drugs (NSAIDs), which carry their own cardiovascular risks, is a factor for physicians to consider.


Q: Is Sedacoron considered a 'strong' medicine?

Regulatory agencies restrict the use of this medicine only to life-threatening heart rhythm issues. This is due to its potential for substantial toxicity, including serious and sometimes fatal lung and liver problems. The use of this drug necessitates strict monitoring protocols.


Q: What happens if I stop taking Sedacoron suddenly?

Discontinuation of the medication requires the supervision of a physician. Even after discontinuation, antiarrhythmic effects, as well as side effects, persist in the body for weeks or months due to its long half-life. Official information states that the recurrence of the original life-threatening heart rhythm issue is unpredictable.


Q: Is Sedacoron available as a generic medicine?

Yes, the active ingredient, amiodarone hydrochloride, is available as a generic medicine. This generic version contains the same active substance as the various brand-name products, including Sedacoron. Generic availability can often provide a lower-cost alternative.


Q: Do I need to change my diet while taking Sedacoron?

Yes, one significant dietary precaution is required by the official prescribing information. Official prescribing information contains a strong warning that patients must completely avoid grapefruit and grapefruit juice. This is because these products can interfere with how the body processes the medication, leading to dangerously increased blood levels of the drug.


Q: Is there a test I need to take before starting Sedacoron?

Yes, regulatory documents specify the need for several baseline tests and assessments before starting the medication. These mandatory tests typically include checks of thyroid and liver function, pulmonary (lung) function tests, and an eye examination. These help establish a baseline for future monitoring.


Q: Can I drink alcohol while using Sedacoron?

Official product information does not specify a major direct interaction with alcohol. However, given the medication's known risk of causing liver toxicity, the liver's role in processing the drug makes minimizing liver stress a consideration for the prescribing physician.


Q: How often do people experience a specific side effect like dizziness with Sedacoron?

Official product information lists dizziness or lightheadedness among the more commonly reported side effects. Incidence rates for side effects can vary depending on the study and the specific form of the drug administered.


Q: Does Sedacoron interact with common over-the-counter supplements?

Yes, Sedacoron is known to interact with certain common over-the-counter supplements. Regulatory information notes potential interactions with products such as St. John's wort, garlic, ginkgo biloba, and potassium, which may alter the drug's levels or increase the risk of side effects.


Q: What is the purpose of the routine monitoring tests needed for Sedacoron?

The routine monitoring tests are required by the monitoring protocol due to the drug's potential for causing toxicity to multiple organ systems. The required blood tests and examinations are intended to monitor the drug's known effects on the lungs, liver, and thyroid gland, as well as to check for any serious adverse changes to the heart's electrical activity.


Q: What is the difference between the brand name Sedacoron and its generic version?

Brand-name products, like Sedacoron, and their generic counterparts contain the exact same active ingredient: amiodarone hydrochloride. Regulatory bodies require that generic versions be bioequivalent, meaning they work the same way in the body. Differences typically relate to cost and the inactive ingredients (excipients) used in the formulation.


Q: Are the side effects of Sedacoron reversible?

Some common side effects are typically reversible upon discontinuation of the medicine. For instance, corneal microdeposits are usually reversible, and the blue-gray skin discoloration resolves slowly over several months. However, official warnings emphasize that serious toxicities, such as lung and liver injury, can be irreversible or fatal.


Q: Can Sedacoron cause mood changes or anxiety?

Yes, official reports mention that the medication can potentially cause certain changes to mood and mental state. Side effects such as confusion, mood changes, and unusual excitement have been reported. Furthermore, anxiety may be a sign of drug-induced hyperthyroidism, which is a known potential toxicity.


Q: Why is Sedacoron used for both ventricular and supraventricular arrhythmias?

The official, approved indication for this medication is strictly limited to life-threatening ventricular arrhythmias. Regulatory agencies have not approved its use for supraventricular arrhythmias (rhythms starting in the upper chambers of the heart). The use of the drug for unapproved conditions is considered off-label.


Q: What are the most common reasons people need to stop taking Sedacoron?

Official clinical trial data indicates that discontinuation is most often due to the occurrence of adverse reactions. These reasons include persistent gastrointestinal side effects, issues like low blood pressure (hypotension), or the development of severe, new heart rhythm issues.


Q: How long does Sedacoron stay in your system after the last dose?

This medication is known for its exceptionally long persistence in the body. Regulatory pharmacokinetics data states that the terminal elimination half-life averages approximately 58 days. Consequently, the drug’s effects and potential for toxicity can persist for weeks or months after the medication is completely stopped.


Q: Is it normal to feel tired in the first few weeks of taking Sedacoron?

Weakness and fatigue are reported as common side effects of this medication. If feelings of tiredness persist or are severe, they may be a signal to adjust the treatment plan.


Q: Is Sedacoron a controlled substance?

No, this medication is not classified as a controlled substance by regulatory bodies. It is a prescription drug intended for specialized use in treating specific life-threatening heart conditions.


Q: What are the long-term safety data themes for Sedacoron?

Official prescribing information highlights that the primary long-term safety concerns involve the potential for toxicity to vital organs. These major concerns center on the lungs (pulmonary toxicity), the liver (hepatic injury), and the thyroid gland (thyroid dysfunction), requiring ongoing medical monitoring.


Q: Are there different strengths of Sedacoron available?

Yes, the oral tablets are available in different dosage strengths. According to official information, common available strengths are 100 mg, 200 mg, and 400 mg. The specific strength prescribed depends on the patient's individual treatment phase.


Q: Does Sedacoron have any known interactions with herbal medicines?

Yes, regulatory documents indicate that Sedacoron can interact with certain herbal medicines. Supplements like St. John’s wort, which can alter how the body processes the drug, are known to interact.


Q: Is Sedacoron used for any conditions outside of heart rhythm management?

No, the official, FDA-approved indication for this drug is exclusively for the treatment of life-threatening ventricular arrhythmias. Use for any other condition is considered off-label and is not covered by the drug's regulatory approval.


Q: Why do official documents emphasize the risk of serious side effects with Sedacoron?

Official documents, including the Boxed Warning, emphasize the risks due to the drug's potential for severe, sometimes fatal toxicities. These serious risks primarily affect the lungs and the liver. This emphasis serves as a critical regulatory warning, necessitating the restriction of the drug's use to only life-threatening cases.


Q: How is Sedacoron cleared from the body?

The medication is cleared from the body predominantly by metabolism in the liver. Regulatory information states that the drug and its products are then eliminated via biliary excretion (through bile into the gastrointestinal tract). Only a minimal amount is excreted via the urine.


Q: Can Sedacoron affect my sense of taste or smell?

Yes, official adverse reaction reports include changes to the senses of taste and smell. Abnormal taste, often described as a bitter or metallic taste, is listed as a less common side effect associated with the medication.


Q: Is Sedacoron suitable for individuals with asthma or COPD?

Due to the known risk of serious lung toxicity, caution is advised for individuals with pre-existing pulmonary conditions. This includes conditions like asthma or COPD. Official information recommends extreme caution or avoidance in patients with decreased lung function.


Q: Is it safe to drive while taking Sedacoron?

Official prescribing information advises caution regarding activities requiring high levels of alertness. Patients experiencing side effects such as dizziness, weakness, or trouble concentrating are cautioned against driving or operating heavy machinery. This precaution is standard for medications that affect the central nervous system.

How should Sedacoron be stored and disposed of?

Amiodarone (Sedacoron) tablets must be stored at Controlled Room Temperature, which is maintained between 20 C and 25 C (68 F and 77 F), with permitted fluctuations up to 30 C.

Storage Requirements

Condition Requirement
Temperature Do not store above 30 C; do not freeze.
Protection Keep protected from light and away from excessive moisture.
Packaging Store in the container it came in and keep the container tightly closed.

Handling and Disposal

The medicine must be stored out of the reach and sight of children. To dispose of unused or expired tablets, follow any specific instructions provided on the drug labeling or utilize a local medicine take-back program. If a take-back program is unavailable, unused medication should be mixed with an undesirable substance (such as used coffee grounds) and placed in a sealed bag before disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sedacoron found in:

A-Z Index: